DIS3L

Summary

DIS3L (DIS3 like exosome 3’-5’ exoribonuclease, HGNC:28698) is a protein-coding gene on chromosome 15q22.31, encoding DIS3-like exonuclease 1 (Q8TF46). Catalytic component of the RNA exosome complex which has 3’->5’ exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events.

The cytoplasmic RNA exosome complex degrades unstable mRNAs and is involved in the regular turnover of other mRNAs. The protein encoded by this gene contains 3’-5’ exoribonuclease activity and is a catalytic component of this complex.

Source: NCBI Gene 115752 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 179 total
• MANE Select transcript: NM_001143688

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28698
Approved symbol	DIS3L
Name	DIS3 like exosome 3’-5’ exoribonuclease
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC4562, FLJ38088, KIAA1955, DIS3L1
Ensembl gene	ENSG00000166938
Ensembl biotype	protein_coding
OMIM	614183
Entrez	115752

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 16 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000319194, ENST00000319212, ENST00000524795, ENST00000525109, ENST00000525134, ENST00000530537, ENST00000530615, ENST00000532293, ENST00000532580, ENST00000562314, ENST00000564909, ENST00000564945, ENST00000565281, ENST00000568874, ENST00000904293, ENST00000904294, ENST00000904295, ENST00000904296, ENST00000904297, ENST00000904298, ENST00000926558, ENST00000926559, ENST00000962294, ENST00000962295

RefSeq mRNA: 13 — MANE Select: NM_001143688 NM_001143688, NM_001323936, NM_001323937, NM_001323938, NM_001323939, NM_001323940, NM_001323941, NM_001323943, NM_001323944, NM_001323945, NM_001323946, NM_001323948, NM_133375

CCDS: CCDS10214, CCDS45286

Canonical transcript exons

ENST00000319212 — 17 exons

Exon	Start	End
ENSE00001876634	66333004	66333898
ENSE00002577847	66293568	66293735
ENSE00003485711	66315036	66315215
ENSE00003488577	66318449	66318618
ENSE00003496727	66323493	66323585
ENSE00003513867	66325831	66326364
ENSE00003518974	66306824	66306952
ENSE00003529590	66320571	66320732
ENSE00003530271	66331875	66332020
ENSE00003568528	66322687	66322934
ENSE00003590825	66311724	66311900
ENSE00003610882	66332736	66332910
ENSE00003641864	66328970	66329124
ENSE00003660796	66294988	66295141
ENSE00003665796	66314039	66314117
ENSE00003678023	66329221	66329399
ENSE00003789283	66308709	66308844

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 95.03.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.7670 / max 127.2513, expressed in 1780 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
147263	8.4199	1728
207569	1.3898	890
147264	0.8150	403
147261	0.6267	349
147262	0.5155	257

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	95.03	gold quality
corpus callosum	UBERON:0002336	93.88	gold quality
tibialis anterior	UBERON:0001385	93.78	gold quality
adrenal tissue	UBERON:0018303	93.58	gold quality
deltoid	UBERON:0001476	92.92	gold quality
skeletal muscle tissue	UBERON:0001134	92.13	gold quality
vastus lateralis	UBERON:0001379	91.97	gold quality
quadriceps femoris	UBERON:0001377	91.94	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	91.94	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.87	gold quality
muscle tissue	UBERON:0002385	91.63	gold quality
calcaneal tendon	UBERON:0003701	91.60	gold quality
muscle of leg	UBERON:0001383	91.48	gold quality
upper arm skin	UBERON:0004263	91.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.12	gold quality
gastrocnemius	UBERON:0001388	91.02	gold quality
inferior vagus X ganglion	UBERON:0005363	91.02	gold quality
superior surface of tongue	UBERON:0007371	91.02	gold quality
body of tongue	UBERON:0011876	90.98	gold quality
subthalamic nucleus	UBERON:0001906	90.97	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.94	gold quality
superior vestibular nucleus	UBERON:0007227	90.90	gold quality
dorsal plus ventral thalamus	UBERON:0001897	90.77	gold quality
tongue	UBERON:0001723	90.70	gold quality
biceps brachii	UBERON:0001507	90.60	gold quality
pons	UBERON:0000988	90.59	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	90.56	gold quality
dorsal root ganglion	UBERON:0000044	90.45	gold quality
medulla oblongata	UBERON:0001896	90.33	gold quality
trigeminal ganglion	UBERON:0001675	90.15	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	1691.71
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

13 targeting DIS3L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-891B	99.59	69.81	1083
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4742-5P	98.89	68.41	1542
HSA-MIR-4712-3P	98.52	65.39	822
HSA-MIR-6742-3P	97.95	64.50	1490
HSA-MIR-1236-5P	96.62	66.38	856
HSA-MIR-369-5P	85.74	63.54	36

Literature-anchored findings (GeneRIF, showing 3)

• Data show that hDIS3 and hDIS3L are active exonucleases, but only hDIS3 has retained endonucleolytic activity, and suggest that three different ribonucleases can serve as catalytic subunits for the exosome in human cells. (PMID:20531386)
• Data indicate that hDis3L1 is a novel exosome-associated exoribonuclease in the cytoplasm of human cells. (PMID:20531389)
• we screened the susceptibility loci for Myocardial infarction (MI) using exome sequencing and validated candidate variants in replication sets. We identified that three genes (GYG1, DIS3L and DDRGK1) were associated with MI at the discovery and replication stages. (PMID:29321365)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	dis3l	ENSDARG00000053200
mus_musculus	Dis3l	ENSMUSG00000032396
rattus_norvegicus	Dis3l	ENSRNOG00000010537

Paralogs (2): DIS3 (ENSG00000083520), DIS3L2 (ENSG00000144535)

Protein

Protein identifiers

DIS3-like exonuclease 1 — Q8TF46 (reviewed: Q8TF46)

All UniProt accessions (6): Q8TF46, E9PI20, E9PI27, E9PIL0, E9PKI7, E9PS35

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic component of the RNA exosome complex which has 3’->5’ exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3’ untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA.

Subunit / interactions. Component of the RNA exosome complex. The catalytically inactive RNA exosome core (Exo-9) complex is believed to associate with catalytic subunits EXOSC10, and DIS3 or DIS3L in cytoplasmic- and nuclear-specific RNA exosome complex forms.

Subcellular location. Cytoplasm.

Similarity. Belongs to the RNR ribonuclease family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8TF46-1	1	yes
Q8TF46-2	2
Q8TF46-3	3
Q8TF46-4	4

RefSeq proteins (13): NP_001137160, NP_001310865, NP_001310866, NP_001310867, NP_001310868, NP_001310869, NP_001310870, NP_001310872, NP_001310873, NP_001310874, NP_001310875, NP_001310877, NP_588616 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001900	RNase_II/R	Domain
IPR012340	NA-bd_OB-fold	Homologous_superfamily
IPR022966	RNase_II/R_CS	Conserved_site
IPR033770	RRP44_S1	Domain
IPR033771	Rrp44_CSD1	Domain
IPR041505	Dis3_CSD2	Domain
IPR050180	RNR_Ribonuclease	Family

Pfam: PF00773, PF17215, PF17216, PF17849

UniProt features (15 total): splice variant 4, domain 3, sequence variant 3, mutagenesis site 3, chain 1, modified residue 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9G8M	ELECTRON MICROSCOPY	3.3
9G8O	ELECTRON MICROSCOPY	3.4
9G8N	ELECTRON MICROSCOPY	3.7
9G8P	ELECTRON MICROSCOPY	7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF46-F1	84.28	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 989

Mutagenesis-validated functional residues (3):

Position	Phenotype
62	no change of exonuclease activity.
166	no change of exonuclease activity.
486	complete loss of exonuclease activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 107 (showing top): RRAGTTGT_UNKNOWN, GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, COUP_01, BILD_E2F3_ONCOGENIC_SIGNATURE, HNF4_01, AACTTT_UNKNOWN, GOMF_EXONUCLEASE_ACTIVITY, GOBP_RRNA_CATABOLIC_PROCESS, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, YNGTTNNNATT_UNKNOWN, SENESE_HDAC3_TARGETS_DN, TGGAAA_NFAT_Q4_01

GO Biological Process (5): RNA processing (GO:0006396), RNA catabolic process (GO:0006401), mRNA catabolic process (GO:0006402), rRNA catabolic process (GO:0016075), gene expression (GO:0010467)

GO Molecular Function (9): 3’-5’-RNA exonuclease activity (GO:0000175), RNA binding (GO:0003723), exoribonuclease II activity (GO:0008859), enzyme binding (GO:0019899), nuclease activity (GO:0004518), exonuclease activity (GO:0004527), RNA nuclease activity (GO:0004540), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (7): cytoplasmic exosome (RNase complex) (GO:0000177), centrosome (GO:0005813), cytosol (GO:0005829), plasma membrane (GO:0005886), ciliary basal body (GO:0036064), exosome (RNase complex) (GO:0000178), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA catabolic process	2
nuclease activity	2
cytoplasm	2
microtubule organizing center	2
cellular anatomical structure	2
intracellular anatomical structure	2
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
RNA metabolic process	1
nucleic acid catabolic process	1
negative regulation of gene expression	1
mRNA metabolic process	1
rRNA metabolic process	1
macromolecule biosynthetic process	1
3’-5’ exonuclease activity	1
RNA exonuclease activity, producing 5’-phosphomonoesters	1
nucleic acid binding	1
3’-5’-RNA exonuclease activity	1
protein binding	1
catalytic activity, acting on a nucleic acid	1
hydrolase activity, acting on ester bonds	1
catalytic activity, acting on RNA	1
binding	1
catalytic activity	1
exosome (RNase complex)	1
centriole	1
membrane	1
cell periphery	1
cilium	1
exoribonuclease complex	1

Protein interactions and networks

STRING

2318 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DIS3L	EXOSC10	Q01780	885
DIS3L	EXOSC9	Q06265	859
DIS3L	EXOSC8	Q96B26	837
DIS3L	EXOSC4	Q9NPD3	814
DIS3L	EXOSC7	Q15024	801
DIS3L	EXOSC3	Q9NQT5	794
DIS3L	EXOSC1	Q9Y3B2	778
DIS3L	EXOSC6	Q5RKV6	740
DIS3L	EXOSC5	Q9NQT4	738
DIS3L	MTREX	P42285	708
DIS3L	XRN1	Q8IZH2	698
DIS3L	C1D	Q13901	659
DIS3L	EXOSC2	Q13868	649
DIS3L	XRN2	Q9H0D6	598
DIS3L	SKIC2	Q15477	591

IntAct

45 interactions, top by confidence:

A	B	Type	Score
EXOSC3	DIS3L	psi-mi:“MI:0915”(physical association)	0.850
EXOSC4	EXOSC10	psi-mi:“MI:0914”(association)	0.840
EXOSC1	EXOSC10	psi-mi:“MI:0914”(association)	0.810
EXOSC3	EXOSC10	psi-mi:“MI:0914”(association)	0.790
EIF4E2	GIGYF1	psi-mi:“MI:0914”(association)	0.730
DIS3L	EXOSC2	psi-mi:“MI:0914”(association)	0.690
MPHOSPH6	MTREX	psi-mi:“MI:0914”(association)	0.690
HBS1L	DIS3L	psi-mi:“MI:0915”(physical association)	0.670
EXOSC5	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
C1D	ZFC3H1	psi-mi:“MI:0914”(association)	0.640
EXOSC3	MTREX	psi-mi:“MI:0914”(association)	0.640
DIS3L	EXOSC9	psi-mi:“MI:0914”(association)	0.600
EXOSC4	MTREX	psi-mi:“MI:0914”(association)	0.530
LCN15	POTEF	psi-mi:“MI:0914”(association)	0.530
EXOSC4	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
EXOSC2	MTREX	psi-mi:“MI:0914”(association)	0.530
EXOSC7	MTREX	psi-mi:“MI:0914”(association)	0.530
MPHOSPH6	ZFC3H1	psi-mi:“MI:0914”(association)	0.530
DIS3L	EIF4E2	psi-mi:“MI:0914”(association)	0.530
DIS3L	SNRNP70	psi-mi:“MI:0914”(association)	0.350
EXOSC1	MPHOSPH6	psi-mi:“MI:0914”(association)	0.350
EXOSC5	PAPD5	psi-mi:“MI:0914”(association)	0.350
EXOSC9	MPHOSPH6	psi-mi:“MI:0914”(association)	0.350
EXOSC4	RPS3	psi-mi:“MI:0914”(association)	0.350
EXOSC2	WDR46	psi-mi:“MI:0914”(association)	0.350
Exosc1	MPHOSPH6	psi-mi:“MI:0914”(association)	0.350

BioGRID (130): DIS3L (Affinity Capture-MS), DIS3L (Affinity Capture-MS), DIS3L (Affinity Capture-MS), DIS3L (Affinity Capture-MS), DIS3L (Affinity Capture-MS), H2AFX (Affinity Capture-MS), EXOSC9 (Affinity Capture-MS), EXOSC10 (Affinity Capture-MS), SNRNP70 (Affinity Capture-MS), HBS1L (Affinity Capture-MS), SRCAP (Affinity Capture-MS), EXOSC8 (Affinity Capture-MS), EXOSC2 (Affinity Capture-MS), GIGYF2 (Affinity Capture-MS), EXOSC3 (Affinity Capture-MS)

ESM2 similar proteins: A0JN80, A2RV18, A2VE39, D2HRF1, D3ZG52, D3ZVK1, E1BMP7, G3GTP0, I0IUP3, O02697, P0DM58, P37202, P42338, P48736, P49717, P49917, Q08162, Q0P4R5, Q0V9Q6, Q0V9R3, Q0WPN0, Q17632, Q3EBC8, Q3V3E1, Q5F310, Q5R5N8, Q5R6L3, Q5R981, Q5U2P0, Q5U2Z5, Q5ZKG3, Q6GN11, Q6NQJ6, Q80VJ4, Q8BTF7, Q8BTI9, Q8C0L9, Q8C0S1, Q8CI75, Q8N1G2

Diamond homologs: A0JN80, A2RV18, O14040, O84402, P0DM58, P37202, Q08162, Q0P4R5, Q0WPN0, Q17632, Q5R5N8, Q5U2P0, Q6GN11, Q6NQJ6, Q8C0S1, Q8CI75, Q8TF46, Q9CSH3, Q9PK00, Q9SHL7, Q9Y2L1, Q9Z848, D0Z8E6, Q09568, Q0V9R3, Q9ZJX9, O32231, O67834, P21499, P30851, P40611, P44907, P47950, P54084, P56123, P57628, Q02146, Q8IYB7, Q8K917, Q9KNY1

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DIS3L	“form complex”	Exosome_Complex	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 42 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA decay by 3’ to 5’ exoribonuclease	8	203.9×	5e-16
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	7	158.6×	2e-13
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	7	158.6×	2e-13
KSRP (KHSRP) binds and destabilizes mRNA	7	158.6×	2e-13
Nuclear RNA decay	12	132.3×	1e-21
ATF4 activates genes in response to endoplasmic reticulum stress	7	102.0×	8e-12
Major pathway of rRNA processing in the nucleolus and cytosol	13	28.7×	7e-15
Metabolism of RNA	6	8.9×	9e-04

GO biological processes:

GO term	Partners	Fold	FDR
maturation of 5.8S rRNA	5	146.3×	3e-09
RNA catabolic process	10	126.5×	4e-17
nuclear-transcribed mRNA catabolic process	5	106.4×	2e-08
RNA processing	9	54.7×	3e-12
rRNA processing	10	39.3×	3e-12

Disease & clinical

Clinical variants and AI predictions

ClinVar

179 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	154
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2941 predictions. Top by Δscore:

Variant	Effect	Δscore
15:66295139:G:GT	donor_gain	1.0000
15:66295139:G:T	donor_gain	1.0000
15:66295142:GTATA:G	donor_loss	1.0000
15:66295143:T:A	donor_loss	1.0000
15:66306823:GACA:G	acceptor_gain	1.0000
15:66308706:CA:C	acceptor_loss	1.0000
15:66308707:A:AC	acceptor_loss	1.0000
15:66308707:A:AG	acceptor_gain	1.0000
15:66308708:G:GA	acceptor_gain	1.0000
15:66308708:GGA:G	acceptor_gain	1.0000
15:66308708:GGAGC:G	acceptor_gain	1.0000
15:66308807:G:GT	donor_gain	1.0000
15:66308821:G:GT	donor_gain	1.0000
15:66308840:TCAAG:T	donor_loss	1.0000
15:66308841:CAAG:C	donor_loss	1.0000
15:66308843:AGG:A	donor_loss	1.0000
15:66308845:G:A	donor_loss	1.0000
15:66308846:T:G	donor_loss	1.0000
15:66311717:A:G	acceptor_gain	1.0000
15:66311721:CA:C	acceptor_loss	1.0000
15:66311722:A:AG	acceptor_gain	1.0000
15:66311723:G:GT	acceptor_gain	1.0000
15:66311723:GA:G	acceptor_gain	1.0000
15:66311723:GAA:G	acceptor_gain	1.0000
15:66311723:GAAT:G	acceptor_gain	1.0000
15:66311723:GAATT:G	acceptor_gain	1.0000
15:66311859:G:GT	donor_gain	1.0000
15:66311899:AGGTG:A	donor_loss	1.0000
15:66311902:T:A	donor_loss	1.0000
15:66318445:A:AG	acceptor_gain	1.0000

AlphaMissense

6958 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:66320629:G:A	G408E	1.000
15:66320601:T:A	W399R	0.999
15:66320601:T:C	W399R	0.999
15:66315080:C:A	R287S	0.998
15:66315081:G:C	R287P	0.998
15:66320628:G:A	G408R	0.998
15:66320628:G:C	G408R	0.998
15:66322786:A:C	S476R	0.998
15:66322788:C:A	S476R	0.998
15:66322788:C:G	S476R	0.998
15:66325841:A:C	S560R	0.998
15:66325843:C:A	S560R	0.998
15:66325843:C:G	S560R	0.998
15:66306887:T:A	N119K	0.997
15:66306887:T:G	N119K	0.997
15:66308768:T:A	V161D	0.997
15:66318587:G:C	R378P	0.997
15:66320631:C:G	H409D	0.997
15:66320590:G:C	R395P	0.996
15:66320603:G:C	W399C	0.996
15:66320603:G:T	W399C	0.996
15:66318590:T:A	I379N	0.995
15:66320587:T:A	V394E	0.995
15:66320613:T:C	S403P	0.995
15:66331999:G:A	G887D	0.995
15:66295030:C:G	P61R	0.994
15:66315075:G:C	R285P	0.994
15:66318449:G:A	G332D	0.994
15:66320623:C:A	P406Q	0.994
15:66320629:G:T	G408V	0.994

dbSNP variants (sampled 300 via entrez): RS1000019122 (15:66323947 T>A,G), RS1000098313 (15:66321444 T>C), RS1000223584 (15:66330285 A>C), RS1000285248 (15:66296061 G>T), RS1000397396 (15:66328166 A>T), RS1000400969 (15:66296330 T>C), RS1000574112 (15:66330625 T>A,C), RS1000745992 (15:66309123 G>A,C), RS1000914897 (15:66302407 GAAGGTGTGAAAACA>G), RS1000999479 (15:66329692 A>C), RS1001054393 (15:66291735 C>CAGGTT), RS1001103155 (15:66323235 T>C), RS1001213096 (15:66311426 G>C), RS1001283502 (15:66303982 C>A,T), RS1001389606 (15:66329438 T>A,G)

Disease associations

OMIM: gene MIM:614183 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002345_17	Response to cytadine analogues (cytosine arabinoside)	5.000000e-06
GCST90002390_418	Mean corpuscular hemoglobin	1.000000e-10
GCST90002392_431	Mean corpuscular volume	1.000000e-10
GCST90002395_176	Mean platelet volume	4.000000e-10
GCST90002397_262	Mean spheric corpuscular volume	2.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
sodium arsenite	decreases expression	2
Dichlorodiphenyl Dichloroethylene	decreases expression, increases expression	2
triphenyl phosphate	affects expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
cupric oxide	decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
ICG 001	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Methotrexate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Tunicamycin	increases expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SK89	HAP1 DIS3L (-) 1	Cancer cell line	Male
CVCL_SK90	HAP1 DIS3L (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer